However, it must be taken into account that the efficacy of currently available therapeutic agents that target the IL-1 system has not yet been satisfactorily demonstrated for MS, despite positive results from preclinical studies and successes in the treatment of other autoimmune diseases [11]. This evidence concerns the gene IL1A and myeloid sarcoma.